Since EDI3 expression is regulated by proteins downstream of PI3K/Akt, which are closely linked to tumour development and progression, we next investigated whether the high EDI3 expression in the ER − HER2 + subtype is associated with improved viability, making it a potential therapeutic target. Here, ERBB2 is linked to neoplasm.